We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
Cap. Flow
-$141M
Cap. Flow %
-5.14%
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$60.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$57M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$40M
4
WBA
Walgreens Boots Alliance
WBA
+$31.6M
5
GMED icon
Globus Medical
GMED
+$26.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$102M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$40.6M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23.8M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$20.7M
5
HCA icon
HCA Healthcare
HCA
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 46.9%
2 Financials 2.94%
3 Technology 0.55%
4 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WBA
26
DELISTED
Walgreens Boots Alliance
WBA
$28.6M 1.04%
+482,000
New +$31.6M
INSM icon
27
Insmed
INSM
$23.5B
$27.1M 0.99%
2,080,160
+874,926
+73% +$13.2M
ELGX
28
DELISTED
Endologix Inc
ELGX
$26.5M 0.97%
250,153
+101,960
+69% +$14.2M
GMED icon
29
Globus Medical
GMED
$10.5B
$25.1M 0.92%
+1,278,235
New +$26.3M
ARNA
30
DELISTED
Arena Pharmaceuticals Inc
ARNA
$24.5M 0.89%
584,800
+147,893
+34% +$6.6M
XNPT
31
DELISTED
XENOPORT, INC.
XNPT
$23.9M 0.87%
4,438,882
+11,240
+0.3% +$54.8K
MCK icon
32
McKesson
MCK
$98.5B
$23.8M 0.87%
122,000
-28,000
-19% -$5.39M
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$23.4M 0.85%
+98,693
New +$25.2M
MNK
34
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$22.5M 0.82%
+250,000
New +$19.6M
VNDA icon
35
Vanda Pharmaceuticals
VNDA
$327M
$22.5M 0.82%
2,168,675
+1,083,374
+100% +$14.2M
TRIV
36
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$22.2M 0.81%
1,532,531
+49,865
+3% +$724K
RNA
37
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$21.9M 0.8%
2,598,459
+392,340
+18% +$3.72M
PACB icon
38
Pacific Biosciences
PACB
$447M
$21.6M 0.79%
4,399,332
-295,871
-6% -$1.55M
LOXO
39
DELISTED
Loxo Oncology, Inc
LOXO
$20.9M 0.76%
+1,591,546
New +$20.6M
TPST icon
40
Tempest Therapeutics
TPST
$15.4M
$18.8M 0.69%
388
-176
-31% -$6.17M
GSK icon
41
GSK
GSK
$104B
$18.4M 0.67%
+320,000
New +$19.6M
ANIP icon
42
ANI Pharmaceuticals
ANIP
$1.8B
$17.2M 0.63%
607,355
– –
KERX
43
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$17M 0.62%
1,233,484
-2,650,925
-68% -$40.6M
OFIX icon
44
Orthofix Medical
OFIX
$468M
$16.5M 0.6%
533,812
– –
AMPH icon
45
Amphastar Pharmaceuticals
AMPH
$871M
$16.5M 0.6%
+1,415,075
New +$14.7M
CI icon
46
Cigna
CI
$74.5B
$15.1M 0.55%
166,929
+9,401
+6% +$879K
IMPR
47
DELISTED
IMPRIVATA, INC COM
IMPR
$15.1M 0.55%
+970,951
New +$14.3M
ATRS
48
DELISTED
Antares Pharma, Inc.
ATRS
$14.3M 0.52%
7,823,618
-1,780,085
-19% -$3.88M
SAGE
49
DELISTED
Sage Therapeutics
SAGE
$14.2M 0.52%
+450,667
New +$13.1M
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.1M 0.51%
557,477
-27,371
-5% -$721K
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2014 Portfolio in Review

As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.

  • Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
  • Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
  • Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
  • Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
  • Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.

Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.